CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people... Show more
CVAC broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 36 similar instances where the stock broke above the upper band. In of the 36 cases the stock fell afterwards. This puts the odds of success at .
The 10-day RSI Indicator for CVAC moved out of overbought territory on June 20, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for CVAC turned negative on June 27, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVAC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved above the 0 level on July 08, 2025. You may want to consider a long position or call options on CVAC as a result. In of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CVAC advanced for three days, in of 250 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 83 cases where CVAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.621) is normal, around the industry mean (17.292). P/E Ratio (5.818) is within average values for comparable stocks, (58.926). CVAC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.456). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (2.004) is also within normal values, averaging (272.270).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CVAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a clinical-stage biopharmaceutical company developing tumour immunotherapy
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
NLSIX | 19.50 | -0.04 | -0.20% |
Neuberger Berman Long Short Instl | |||
IEGYX | 23.80 | -0.13 | -0.54% |
Invesco EQV Intl Small Company Y | |||
WCMWX | 17.67 | -0.12 | -0.67% |
WCM Focused Emerging Mkts Ex Chn Inst | |||
FTSIX | 38.22 | -0.31 | -0.80% |
FullerThaler Behvrl S-M Cor Eq Instl | |||
ESCQX | 10.94 | -0.16 | -1.44% |
Embark Small Cap Equity Retirement |
A.I.dvisor indicates that over the last year, CVAC has been loosely correlated with AIM. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CVAC jumps, then AIM could also see price increases.
Ticker / NAME | Correlation To CVAC | 1D Price Change % | ||
---|---|---|---|---|
CVAC | 100% | +0.18% | ||
AIM - CVAC | 44% Loosely correlated | -2.85% | ||
BNTX - CVAC | 40% Loosely correlated | -0.90% | ||
MRNA - CVAC | 40% Loosely correlated | -1.87% | ||
IMNM - CVAC | 39% Loosely correlated | -3.46% | ||
AXON - CVAC | 39% Loosely correlated | -0.46% | ||
More |